Current Grant Support
NIH/NIAID & University of Washington (R21 AI166120), “Microengineered Lollipop for Patient-Centric Saliva Collection” (2022-2023). DeMuri, MPI; Wald, Co-Investigator
UW WPP/PERC, “Safe and Healthy Schools (SHS)” (2021-2022). Wald, PI
NIH/NICHD (OT2 HD107558), “ReSET: Restarting Safe Education and Testing for Children with Medical Complexity” (2021-2022). DeMuri, Co-PI; Wald, Co-Investigator
NIH/NIDDK (T32 DK077586), “Childhood Diabetes and Adiposity Research Training Program (C-DART)” (2020-2025). Wald, Associate Director
NIH/NIAID & Binghamton University (R21 AI147502), “Transcriptomic and genetic differences of group A streptococcus in humans: Acute infection versus carriage” (2019-2021). Wald, Co-PI; DeMuri, Co-Investigator
NIH/NIAID (R21 AI144744), “Nasal cytokine responses in children with viral upper respiratory infection” (2019-2021). Wald, PI; DeMuri, Co-Investigator
NIH/NIAID & University of Pittsburgh (U01 AI118506), “Efficacy of antibiotics in children with acute sinusitis: which subgroups benefit” (2015-2020). Wald, Co-PI; DeMuri, Investigator
Merck Sharp & Dohme Corp, “Double-blind, randomized, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of MK-1654 in pre-term and full-term infants” (2018-ongoing). Wald, PI; DeMuri, Co-Investigator
Merck Sharp & Dohme Corp, “A phase 3, multicenter, randomized, double-blind, active comparator controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEU-LINK)” (2018-ongoing). Wald, PI; DeMuri, Co-Investigator
Completed Grant Support
Roche, “Comparison of sensitivity and specificity of detection of Group A streptococcus from pharyngeal and lolly pop specimens” (2018-2019). Wald, PI; DeMuri, Co-Investigator
MedImmune, Inc., “A phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of MEDI8897, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy preterm infant” (2017-2019). Wald, PI; DeMuri, Co-Investigator
Janssen Research & Development, “A phase 2, randomized double-blind placebo-controlled study to evaluate antiviral activity clinical outcomes safety tolerability, & pharmacokinetics of orally administered Lumicitabine (JNJ-64041575) regimens in hospitalized infants & children with RSV” (2017-2019). Wald, PI; DeMuri, Co-Investigator
NIH/NIAID (R01 AI097172), “Sinusitis in children and the nasopharyngeal microbiome” (2011-2017). Wald, PI; DeMuri, Co-Investigator
Regeneron Pharmaceuticals, Inc., “A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a human monoclonal antibody, REGN2222, for the prevention of medically attended RSV infection in preterm infants” (2015-2017). Wald, PI; DeMuri, Co-Investigator
Cubist Pharmaceuticals, Inc., “CUBEXA-01: a multicenter, randomized, double-blinded comparative study to evaluate the efficacy, safety, and pharmacokinetics of Ceftaroline or Daptomycin versus active comparator in pediatric subjects with acute hematogenous osteomyelitis due to gram-po” (2013-2017). Wald, PI; DeMuri, Co-Investigator
Thrasher Research Fund, “short (5 days) versus long (14 days) duration of antimicrobial therapy for acute bacterial sinusitis in children” (2010-2016). Wald, PI; DeMuri, Co-Investigator
NIH/NIDDK & University of Pittsburgh (R01 DK087870), “Corticosteroids for children with febrile urinary tract infections” (2011-2016). Wald, Co-Investigator
Hoffmann-LaRoche, Inc., “BP28947, a screening protocol to assess adult and adolescent individuals with down syndrome for eligibility to participate in an upcoming study to evaluate the efficacy, safety and tolerability of RO5186582” (2013-2016). Wald, PI
GlaxoSmithKline, “Immunogenicity and safety study of GSK Biologicals Infanrix hexa at 2, 4 and 6 months of age in healthy infants” (2014-2015). Wald, PI
GlaxoSmithKline, “A phase IIIA, blinded, randomized, controlled, multinational consistency study to evaluate the immunogenicity and safety of gsk biologicals’ MMR vaccine (209762) compared to Merck & Co., Inc.’s MMR vaccine as a first dose, both co-administered with Varivax, Havrix and Prevnar 13 to healthy children 12 to 15 months of age” (2013-2015). Wald, PI
NIH/NICHD (R21 HD068783), “An interactive web-based intervention to achieve healthy weight in young children” (2012-2015). Wald, PI
GlaxoSmithKline, “A phase III, randomized, multicenter study, doubleblind for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals’ Haemophilus influenza type B (Hib) conjugate vaccine and single blind and controlled for the evaluation and safety and GSK Biologicals Hib vaccine 208108 compared to the monovalent Hib vaccine ActHIB and open for comparison with the combined DTPA-IPV-Hib vaccine Pentacel when administered to healthy infants at 2, 4, 6 and 15-18 months of age with recommended co-administrations at separate sites” (2010-2014). Wald, PI
MedImmune, Inc., “An observational prospective study to assess the outcomes and risk factors of RSV infection among premature infants (32-35 weeks gestational age)” (2009-2012). Wald, PI
Merck & Company, Inc., “Protocol V503-005 – the immunogenicity and tolerability of V503 given concomitantly with Menactra & Adacel in preadolescents (11 to 15 year olds)” (2009-2011). Wald, PI
NIH/NIDDK & University of Pittsburgh (U01 DK074053), “Efficacy of prophylactic antimicrobials with vesicoureteral reflux” (2007-2010). Wald, Co-Investigator
NIH/NIAID & University of Pittsburgh (R21 AI076677), “Diagnosing acute bacterial sinusitis in children and measuring treatment response” (2008-2010). Wald, Co-Investigator
GlaxoSmithKline, “110058/054: Immunogenecity of MMRV vs ProQuad when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months age” (2007-2010). Wald, PI
DHHS/AHRQ (R21 HS014862), “Treatment of children with obesity in primary care” (2006-2009). Wald, PI
Boehringer Ingelheim, Ltd., “Predictors of constipation in healthy children” (2006-2009). Wald, PI
GlaxoSmithKline, “A phase III, single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals’ Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (Hib-MenCY-TT) compared to monovalent Haemophilus influenzae type b (Hib) control vaccine in healthy infants at 2,4,6,and 12 to 15 months of age” (2006-2009). Wald, PI
GlaxoSmithKline, “Immunogenicity and safety study of a booster dose of GSK Biologicals MenACWY” (2008). Wald, PI
NIH/NIAID & Children’s Hospital of Pittsburgh (U01 AI066007), “Efficacy of antimicrobials in young children with AOM” (2007-2008). Wald, Co-Investigator
AstraZeneca AB & Children’s Hospital of Pittsburgh, “IRUSMERO0103: extended spectrum beta-lactamase surveillance in pediatric isolates of enterobacter clocae: multicenter surveillance” (2007-2008). Wald, Co-Investigator